- Home
- Mea Lymphedema Treatment Market
MEA Lymphedema Treatment Market - Industry Trends and Forecast to 2029
- Published Date: September, 2022 | Report ID: CLS-158 | No of pages: 203 | Format:
Middle East and Africa lymphedema treatment market is projected to register a substantial CAGR of 5.3% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2020 and the forecast period is 2022 to 2029
Market Segmentation:
Middle East and Africa Lymphedema Treatment Market, Treatment Type (Compression Therapy, Surgery, Drug Therapy, Laser Therapy, Others), Type (Secondary Lymphedema, Primary Lymphedema), Affected Area (Lower Extremity, Upper Extremity, Genitalia), Age Group (Adult, Geriatric, Pediatric), Route of Administration (Oral, Injectable, Topical), End User (Hospital, Speciality Clinics, Ambulatory Surgical Centers, Others) Distribution Channel (Pharmacy Stores, Direct Tender, Others) Country (Saudi Arabia, South Africa, U.A.E., Egypt, Kuwait, Israel, and Rest of Middle East and Africa) Industry Trends and Forecast to 2029
Some of the factors that drives the growth of the Middle East and Africa lymphedema treatment market are:
Rising prevalence of the diseases
Increasing healthcare expenditure
Market Players:
The key market players for Middle East and Africa lymphedema treatment market are listed below:
medi GmbH & Co. KG
PAUL HARTMANN AG
3M
Convatec Inc.
JUZO
SIGVARIS GROUP
Mego Afek ltd.
Cardinal Health
Essity (BSN medical GmbH)
HERANTIS PHARMA Plc
Huntleigh Healthcare Limited
TABLE OF CONTENT
TABLE OF CONTENTS
1 INTRODUCTION 42
1.1 OBJECTIVES OF THE STUDY 42
1.2 MARKET DEFINITION 42
1.3 OVERVIEW OF MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET 42
1.4 LIMITATIONS 44
1.5 MARKETS COVERED 44
2 MARKET SEGMENTATION 47
2.1 MARKETS COVERED 47
2.2 GEOGRAPHICAL SCOPE 48
2.3 YEARS CONSIDERED FOR THE STUDY 49
2.4 CURRENCY AND PRICING 49
2.5 DBMR TRIPOD DATA VALIDATION MODEL 50
2.6 MULTIVARIATE MODELLING 53
2.7 PRODUCT TYPE LIFELINE CURVE 54
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 54
2.9 DBMR MARKET POSITION GRID 56
2.10 MARKET APPLICATION COVERAGE GRID 57
2.11 VENDOR SHARE ANALYSIS 58
2.12 SECONDARY SOURCES 59
2.13 ASSUMPTIONS 59
3 EXECUTIVE SUMMARY 60
4 PREMIUM INSIGHTS 64
4.1 PESTEL'S ANALYSIS 66
4.2 PORTER'S MODEL 67
5 PIPELINE ANALYSIS FOR MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET 68
6 EPIDEMIOLOGY 69
7 REGULATORY GUIDELINES FOR MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET 70
7.1 U.S. 70
7.2 EUROPE 71
7.3 INDIA 71
7.4 MEXICO 72
7.5 CANADA 72
8 MARKET OVERVIEW 74
8.1 DRIVERS 76
8.1.1 RISE IN THE NUMBER OF LYMPHEDEMA CASES MIDDLE EAST & AFRICALY 76
8.1.2 INCREASE IN THE PREVALENCE OF CANCERS 76
8.1.3 INCREASING NUMBER OF HEALTHCARE FACILITIES 77
8.1.4 MULTIPLE THERAPIES 77
8.2 RESTRAINTS 78
8.2.1 HIGH COST OF TREATMENT 78
8.2.2 LACK OF AWARENESS ABOUT THE DISEASE 79
8.3 OPPORTUNITIES 79
8.3.1 DRUG APPROVALS 79
8.3.2 PARTNERSHIP AND AGREEMENT BY MAJOR PLAYERS 80
8.4 CHALLENGES 80
8.4.1 NO PERMANENT CURE FOR LYMPHEDEMA 80
8.4.2 DIFFICULT REIMBURSEMENT 81
9 IMPACT OF COVID-19 ON THE MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET 82
9.1 IMPACT ON PRICE 82
9.2 IMPACT ON DEMAND 82
9.3 IMPACT ON SUPPLY CHAIN 83
9.4 STRATEGIC DECISIONS OF GOVERNMENT AND MANUFACTURERS 83
9.5 CONCLUSION 83
10 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE 85
10.1 OVERVIEW 86
10.2 COMPRESSION THERAPY 89
10.2.1 BY PRODUCT 89
10.2.1.1 COMPRESSION PUMPS 89
10.2.1.2 COMPRESSION GARMENTS 89
10.2.1.2.1 COMPRESSION STOCKINGS 90
10.2.1.2.2 COMPRESSION SLEEVES 90
10.2.1.2.3 OTHERS 90
10.2.1.3 COMPRESSION BANDAGES & WRAPS 90
10.2.1.4 OTHERS 90
10.2.2 BY TECHNIQUE 91
10.2.2.1 STATIC COMPRESSION THERAPY 91
10.2.2.2 DYNAMIC COMPRESSION THERAPY 91
10.3 SURGERY 91
10.3.1 LYMPHOVENOUS TRANSPLANT 92
10.3.2 LYMPHATICOVENOUS ANASTOMOSIS 92
10.3.3 LIPOSUCTION 92
10.3.4 OTHERS 92
10.4 DRUG THERAPY 92
10.4.1 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) 93
10.4.2 RETINOIDS 93
10.4.3 ANTIBIOTICS 93
10.4.4 OTHERS 93
10.5 LASER THERAPY 94
10.6 OTHERS 95
11 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET, BY TYPE 96
11.1 OVERVIEW 97
11.2 SECONDARY LYMPHEDEMA 100
11.3 PRIMARY LYMPHEDEMA 100
11.3.1 LYMPHEDEMA PRAECOX (MEIGE DISEASE) 101
11.3.2 CONGENITAL LYMPHEDEMA 101
11.3.3 LYMPHEDEMA TARDA 101
12 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA 102
12.1 OVERVIEW 103
12.2 LOWER EXTREMITY 106
12.3 UPPER EXTREMITY 106
12.4 GENITALIA 107
13 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP 108
13.1 OVERVIEW 109
13.2 ADULT 112
13.3 GERIATRIC 112
13.4 PEDIATRIC 113
14 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 114
14.1 OVERVIEW 115
14.2 ORAL 118
14.3 INJECTABLE 118
14.4 TOPICAL 119
15 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET, BY END USER 120
15.1 OVERVIEW 121
15.2 HOSPITAL 124
15.3 SPECIALTY CLINICS 124
15.4 AMBULATORY SURGICAL CENTERS 125
15.5 OTHERS 125
16 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL 126
16.1 OVERVIEW 127
16.2 PHARMACY STORES 130
16.3 DIRECT TENDER 130
16.4 OTHERS 131
17 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET, BY REGION 132
17.1 MIDDLE EAST AND AFRICA 133
17.1.1 SOUTH AFRICA 141
17.1.2 SAUDI ARABIA 145
17.1.3 EGYPT 149
17.1.4 U.A.E 153
17.1.5 ISRAEL 157
17.1.6 KUWAIT 161
17.1.7 REST OF MIDDLE EAST AND AFRICA 165
18 MIDDLE EAST & AFRICA LYMPHEDEMA TREATMENT MARKET: COMPANY LANDSCAPE 166
18.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 166
19 SWOT ANALYIS 167
20 COMPANY PROFILE 168
20.1 TACTILE MEDICAL 168
20.1.1 COMPANY SNAPSHOT 168
20.1.2 REVENUE ANALYSIS 168
20.1.3 COMPANY SHARE ANALYSIS 169
20.1.4 PRODUCT PORTFOLIO 169
20.1.5 RECENT DEVELOPMENT 169
20.1.6 CLINICAL TRIAL: 169
20.2 ESSITY (BSN MEDICAL GMBH) 170
20.2.1 COMPANY SNAPSHOT 170
20.2.2 COMPANY SHARE ANALYSIS 170
20.2.3 PRODUCT PORTFOLIO 170
20.2.4 RECENT DEVELOPMENT 171
20.3 3M 172
20.3.1 COMPANY SNAPSHOT 172
20.3.2 REVENUE ANALYSIS 172
20.3.3 COMPANY SHARE ANALYSIS 173
20.3.4 PRODUCT PORTFOLIO 173
20.3.5 RECENT DEVELOPMENTS 173
20.3.6 NEW BUSINESS SEGMENT 173
20.3.7 ACQUISITION 174
20.4 CARDINAL HEALTH 175
20.4.1 COMPANY SNAPSHOT 175
20.4.2 REVENUE ANALYSIS 175
20.4.3 COMPANY SHARE ANALYSIS 176
20.4.4 PRODUCT PORTFOLIO 176
20.4.5 RECENT DEVELOPMENT 176
20.5 LOHMANN & RAUSCHER GMBH & CO. KG 177
20.5.1 COMPANY SNAPSHOT 177
20.5.2 COMPANY SHARE ANALYSIS 177
20.5.3 PRODUCT PORTFOLIO 178
20.5.4 RECENT DEVELOPMENT 178
20.6 AIROS MEDICAL, INC. 179
20.6.1 COMPANY SNAPSHOT 179
20.6.2 PRODUCT PORTFOLIO 179
20.6.3 RECENT DEVELOPMENT 179
20.6.4 PRODUCT LAUNCH: 179
20.7 AVET PHARMACEUTICALS INC. 180
20.7.1 COMPANY SNAPSHOT 180
20.7.2 PRODUCT PORTFOLIO 180
20.7.3 RECENT DEVELOPMENT 180
20.8 BIOCOMPRESSION SYSTEMS 181
20.8.1 COMPANY SNAPSHOT 181
20.8.2 PRODUCT PORTFOLIO 181
20.8.3 RECENT DEVELOPMENT 182
20.8.4 AGREEMENT 182
20.9 CONVATEC INC. 183
20.9.1 COMPANY SNAPSHOT 183
20.9.2 PRODUCT PORTFOLIO 183
20.9.3 RECENT DEVELOPMENT 183
20.10 HERANTIS PHARMA PLC 184
20.10.1 COMPANY SNAPSHOT 184
20.10.2 RECENT DEVELOPMENT 184
20.11 HUNTLEIGH HEALTHCARE LIMITED 185
20.11.1 COMPANY SNAPSHOT 185
20.11.2 PRODUCT PORTFOLIO 185
20.11.3 RECENT DEVELOPMENT 185
20.12 JUZO 186
20.12.1 COMPANY SNAPSHOT 186
20.12.2 PRODUCT PORTFOLIO 186
20.12.3 RECENT DEVELOPMENT 186
20.13 KOYA MEDICAL 187
20.13.1 COMPANY SNAPSHOT 187
20.13.2 PRODUCT PORTFOLIO 187
20.13.3 RECENT DEVELOPMENT 187
20.13.4 APPROVAL 187
20.14 MEDI GMBH & CO. KG 188
20.14.1 COMPANY SNAPSHOT 188
20.14.2 PRODUCT PORTFOLIO 188
20.14.3 RECENT DEVELOPMENT 188
20.15 MEGO AFEK LTD 189
20.15.1 COMPANY SNAPSHOT 189
20.15.2 PRODUCT PORTFOLIO 189
20.15.3 RECENT DEVELOPMENT 190
20.15.4 APPLICATION LAUNCH: 190
20.16 PAUL HARTMANN AG 191
20.16.1 COMPANY SNAPSHOT 191
20.16.2 REVENUE ANALYSIS 191
20.16.3 PRODUCT PORTFOLIO 192
20.16.4 RECENT DEVELOPMENTS 192
20.17 SANYLEG SRL A SOCIO UNICO 193
20.17.1 COMPANY SNAPSHOT 193
20.17.2 PRODUCT PORTFOLIO 193
20.17.3 RECENT DEVELOPMENT 193
20.18 SIGVARIS GROUP 194
20.18.1 COMPANY SNAPSHOT 194
20.18.2 PRODUCT PORTFOLIO 194
20.18.3 RECENT DEVELOPMENTS 195
20.18.4 PRODUCT LAUNCHES: 195
20.19 SMITH +NEPHEW 196
20.19.1 COMPANY SNAPSHOT 196
20.19.2 REVENUE ANALYSIS 196
20.19.3 PRODUCT PORTFOLIO 197
20.19.4 RECENT DEVELOPMENT 197
20.20 THERMOTEK 198
20.20.1 COMPANY SNAPSHOT 198
20.20.2 PRODUCT PORTFOLIO 198
20.20.3 RECENT DEVELOPMENT 198
21 QUESTIONNAIRE 199
22 RELATED REPORTS 203
Segmentation
Short Description:
Middle East and Africa Lymphedema Treatment Market, By Treatment Type (Compression Therapy, Surgery, Drug Therapy, Laser Therapy and Others), Treatment (Primary Lymphedema and Secondary Lymphedema), Affected Area (Genital, Lower Extremity, Upper Extremity and Others), Age Group (Adult and Geriatric), Route of Administration (Oral, Injectable and Others), End User (Hospitals, Ambulatory Surgical Centres, Speciality Clinics and Others), Distribution Channel (Direct Tender, Pharmacy Stores, and Others), Country (South Africa, Saudi Arabia, U.A.E., Kuwait, Israel, and Rest of Middle East and Africa) Industry Trends and Forecast to 2029
Market Definition:
Lymphedema refers to swelling that generally occurs in upper and lower extremities. Sometimes both arms and both legs swell. Lymphedema is most commonly caused by the removal of or damage to lymph nodes as a part of cancer treatment. It results from a blockage in lymphatic system, which is part of immune system. Stems from a damaged lymphatic system, can lead to infections, disfigurement, debilitating pain and disability. There is no cure for lymphedema.
Lymphedema treatment involves multiple therapies instead of standard treatment, since the patients are dissatisfied or dont get cured with the conventional treatment of lymphedema. They approach the alternative treatment which offers more control over health care decisions, and the alternatives are found to be more compatible with the patients health system.
Lymphedema can occur after any cancer or its treatment that affects lymph node drainage. It has been reported to occur within days and up to 30 years after treatment for breast cancer. The initial stage lymphedema treatments are therapies, surgeries and lymphovenous transplant among others. But there is no permanent cure for lymphedema.
Market Segmentation:
Middle East and Africa lymphedema treatment market is categorized into seven notable segments which are by treatment type, type, affected area, age group, route of administration, end user, and distribution channel.
On the basis of treatment type, Middle East and Africa lymphedema treatment market is segmented in compression therapy, surgery, drug therapy, laser therapy and others
On the basis of type, Middle East and Africa lymphedema treatment market is segmented in primary lymphedema and secondary lymphedema
On the basis of affected area, Middle East and Africa lymphedema treatment market is segmented genital, lower extremity and upper extremity
On the basis of age group, the Middle East and Africa lymphedema treatment market is segmented into adult and geriatric
On the basis of route of administration, Middle East and Africa lymphedema treatment market is segmented in oral, injectable and others
On the basis of end user, Middle East and Africa lymphedema treatment market is segmented in hospitals, ambulatory surgical centres, speciality clinics and others
On the basis of distribution channel, Middle East and Africa lymphedema treatment market is segmented in direct tender, pharmacy stores and others
Market Players:
The key market players for the Middle East and Africa lymphedema treatment market are listed below:
Mego Afek ltd
Cardinal Health
Smith+Nephew
SIGVARIS GROUP
medi GmbH & Co. KG
PAUL HARTMANN AG
Convatec Inc.
3M
Juzo
Huntleigh Healthcare Limited
HERANTIS PHARMA Plc
Methodology
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
© 2025 Cognate Lifesciences. All Rights Reserved.